ATR和POLA1之间的合成致死性揭示了个性化癌症治疗的潜在新目标
Hanna Elisabeth Schneider1, Lisa-Maria Schmitt2, Albert Job2
1Center for Tumor Biology and Immunology, Department of Gastroenterology, Endocrinology and Metabolism, University Hospital of Marburg, Philipps-University Marburg, Marburg, Germany; Department of Medicine A - Hematology, Oncology and Pneumology, University Hospital Münster, Muenster, Germany.
概括
在ATR/CHK1通路和DNA聚合酶POLA1之间的合成致命性为癌症治疗提供了新的途径. 缺乏ATR的细胞对POLA1抑制剂的敏感性增加,这表明有针对性的治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 该ATR-CHK1通路对于DNA损伤反应至关重要,也是癌症治疗的关键目标.
- 在ATR抑制剂和DNA修复基因之间的合成致死性有助于它们的抗癌作用.
- 之前的研究确定了POLD1和PRIM1作为ATR的潜在合成致命合作伙伴.
研究的目的:
- 为了验证和描述ATR和DNA聚合酶POLA1.1.之间的合成致死性.
- 研究ATR缺乏细胞对POLA1抑制的敏感性背后的机制.
- 探索在癌症治疗中准ATR/CHK1-POLA1轴的潜力.
主要方法:
- 利用了ATR缺乏的DLD-1人类结直肠癌细胞.
- 采用POLA1的化学抑制和siRNA介导的POLA1耗尽.
- 通过流细胞计 (FACS) 和西式涂抹分析了细胞周期和亡标记.
- 在POLA1耗尽后,对ATR/CHK1抑制剂的各种癌细胞系的评估灵敏度.
主要成果:
- 缺乏ATR的细胞对POLA1抑制剂的敏感性增加,其特征是亡和S相停止.
- 在ATR缺乏细胞中,siRNA介导的POLA1耗尽模仿了化学抑制效应,证实了合成致死性.
- POLA1的枯竭使癌细胞对ATR和CHK1抑制剂敏感,这表明存在相互关系.
- 在ATR/CHK1通路和POLA1.1之间确认了合成致命性.
结论:
- 在ATR/CHK1和POLA1之间的合成致死性为个性化癌症治疗提供了一个有前途的战略.
- POLA1的改变可以作为对ATR/CHK1抑制剂敏感性的生物标志物.
- ATR-CHK1通路的改变可以预测对POLA1抑制剂的敏感性.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Lethal Alleles
15.4K
Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
15.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


